




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵: A61M 15/00	A1	(11) International Publication Number: WO 94/19041 (43) International Publication Date: 1 September 1994 (01.09.94)
(21) International Application Number: PCT/GB94/00388 (22) International Filing Date: 28 February 1994 (28.02.94) (30) Priority Data: 9304011.1 27 February 1993 (27.02.93) GB 9311646.5 5 June 1993 (05.06.93) GB (71) Applicant (for all designated States except US): FISONS PLC [GB/GB]; Fison House, Princes Street, Ipswich, Suffolk IP1 1QH (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): CHAWLA, Brindra, Paul, Singh [GB/GB]; 45 Boundary Road, West Bridgford, Not- tingham NG2 7BZ (GB). (74) Agent: WRIGHT, Robert, Gordon, McRae; Fisons plc, 12 Derby Road, Loughborough, Leicestershire LE11 0BB (GB).	(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	

(54) Title: INHALATION DEVICE**(57) Abstract**

A device for the administration of powdered inhalation medicament contained initially in a capsule having at least one aperture formed therein, comprising a swirl chamber (1) adapted to receive the medicament capsule; a mouthpiece (2) communicating with the swirl chamber (1) and separated therefrom by a grid (4); at least one air inlet (5) in tangential communication with the swirl chamber (1) whereby air can be drawn through the device via the mouthpiece (2) to cause a swirling air flow through the swirl chamber (1); and a cover member (7), having a continuous substantially planar inner surface, provided on the base of the swirl chamber (1) remote from the mouthpiece (2); said cover (7) being moveable between a first position in which the capsule can be inserted into the swirl chamber (1) and a second position in which the capsule is retained in the swirl chamber (1) and rotates upon air being drawn through the device, thereby dispensing the medicament contained therein.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

INHALATION DEVICE

This invention relates to an inhalation device, in particular to an inhalation device for use with pre-pierced capsules of dry powder medicament.

The administration of inhalation medicaments in dry powder form is well known.

5 Powdered medicament is often supplied in capsules which are loaded into a dispensing device wherein the medicament is released from the capsule then inhaled by the patient.

Powdered medicament contained in a capsule may be dispensed using the device known as the SPINHALER™. This device comprises a housing which retains an individual capsule of medicament which is pierced *in situ* thus releasing the medicament
10 for inhalation. This device has the disadvantage that small fragments of the capsule may be produced during the opening process which could be inhaled by the patient. Furthermore, the design of piercing mechanism may limit the device to use with medicament capsules of only one size.

European Patent Application 0333334 discloses a device for the administration
15 of medicament from capsules in which the capsule is pierced prior to its insertion in a dispensing chamber by pushing it onto a pin located in a recess in the base of the dispensing chamber. This device suffers from the disadvantage that it is only possible to pierce one end of the capsule at a time. Thus if it is desired to pierce the capsule at both ends to assist the release of medicament, the piercing procedure must be
20 repeated with the possibility of losing medicament from the first aperture whilst the second is being formed. Furthermore, the recess provided in the base of the dispensing chamber provides an area in which medicament can become trapped possibly reducing the dose administered to the patient and/or making cleaning the device more difficult.

Pre-pierced medicament capsules, i.e. capsules the walls of which are provided
25 with one or more apertures during manufacture, are known. European Patent Application 0385156 discloses a disposable inhaler containing a single pre-pierced capsule. However, this device suffers from the drawback that it may be necessary to carry several separate devices in order to provide a day's supply of medicament. It is also wasteful since the device cannot be refilled and is thus discarded after only one use.

30 We have now devised an improved inhalation device which overcomes or substantially mitigates the disadvantages of the prior art devices described above.

According to the invention there is provided a device for the administration of powdered inhalation medicament contained initially in a capsule having at least one

aperture formed therein, said device comprising a swirl chamber adapted to receive the medicament capsule; a mouthpiece communicating with the swirl chamber and separated therefrom by a grid; at least one air inlet in tangential communication with the swirl chamber whereby air can be drawn through the device via the mouthpiece to
5 cause a swirling air flow through the swirl chamber; and a cover member, having a continuous substantially planar inner surface, provided on the base of the swirl chamber remote from the mouthpiece; said cover being moveable between a first position in which the capsule can be inserted into the swirl chamber and a second position in which the capsule is retained in the swirl chamber and rotates upon air being drawn through
10 the device, thereby dispensing the medicament contained therein.

The cover member may be removably attached to the base of the swirl chamber remote from the mouthpiece, e.g. by a snap-fit or screw-threaded engagement. Alternatively, the cover member may be slidably attached to the base of the swirl chamber to provide access thereto. However, we prefer the cover member to be in
15 hinged engagement with the base of the swirl chamber, pivotal movement about the hinge allowing the cover to move between the first and second positions. When the cover member is in hinged engagement with the swirl chamber the cover member is preferably adapted to resiliently engage a flange on the swirl chamber at a position remote from the hinge. This resilient engagement ensuring that, when in the second
20 position, the cover member remains closed.

The cover member may be made of a transparent material, thus allowing the patient to readily determine if all the medicament contained in the capsule has been inhaled.

When the cover member is in the second position the continuous substantially
25 planar inner surface of the cover member defines the base of the swirl chamber. The continuous substantially planar surface of the cover member provides an effective seal at the base of the swirl chamber thus preventing the escape of medicament. It also facilitates rotation of the capsule within the swirl chamber.

The device according to the invention may have any practicable number of air
30 inlets in tangential communication with the swirl chamber. We prefer the device to have two air inlets in tangential communication with the swirl chamber. The air inlets are preferably spaced at regular intervals around the swirl chamber.

The mouthpiece of the device may also be provided with a removable cover to

help prevent the ingress of dirt and moisture between uses. When the device is provided with a mouthpiece cover it is preferably adapted to cover the both the mouthpiece and the air inlet(s) communicating with the swirl chamber. The mouthpiece cover is preferably provided with protruding element(s) adapted to cover the air inlet(s).

5 The device according to the invention can be used in a manner which depends only upon the inspiration of the patient to achieve dispersion of the medicament contained in the capsule. It can also be used in a positive gas assisted manner in which an external source of gas, e.g. air, is used to assist rotation of the capsule in the swirl chamber. The external source of gas may be provided manually or electrically, using, 10 for example, a compressed gas cylinder or air compressor. The use of the device in a gas assisted manner may be particularly useful for patients who have low inspiration rates, e.g. infants, the elderly or patients at a critical stage of an asthma attack.

The capsules for use in the device according to the invention may be made from any material in which apertures may be formed, suitable materials include hard or soft 15 gelatin, polystyrene, nylons, polyalkylenes such as polyethylene, cellulose, alkyl cellulose and acetate polymers.

The capsules may be of any shape but are preferably cylindrical. The capsules may contain one or more apertures, e.g. 1 to 6, and especially 2 apertures. The apertures may be situated in any portion of the capsule body. However, when the 20 capsules are cylindrical we prefer them to have an aperture situated at the end of the capsule and more preferably at both ends of the capsule.

The capsule apertures may be of any shape, e.g. square, rectangular, oval, or preferably circular. When the apertures are circular they may have a diameter of between 0.50 and 1.20 mm, preferably from 0.50 to 1.01 mm, more preferably from 0.76 25 to 1.01 mm and especially 0.81 mm. When the capsule contains more than one aperture then the apertures may have the same or different dimensions.

The method used for forming the capsule apertures will be dependent upon the size, shape and position of the apertures, any conventional techniques known *per se* may be employed. When a circular or oval aperture is required a cutting tool may be used; 30 alternatively laser light may be employed or a hot needle. When a square or rectangular aperture is required a cutting tool with an inclined terminal face may be employed.

The capsules for use in the device according to the invention may be provided

in a blister-pack adapted to seal the capsule aperture(s) until they are removed from the pack, as described in International Patent Application PCT/GB93/01909.

Although the device according to the invention has thus far been described for use in oral inhalation of medicaments, it is also suitable for the administration of nasal
5 medicaments by inhalation. The necessary adaptation for this mode of administration will be readily apparent to those skilled in the art and may take the form of an elongate air passage adapted for insertion into the nostril rather than a mouthpiece.

The device may be used for dispensing any medicament which is conventionally administered by inhalation to the lung or the nose. Such medicaments include drugs for
10 use in the prophylactic or remedial treatment of reversible obstructive airways disease. Specific active ingredients which may be mentioned include salts of cromoglycic acid, e.g. sodium cromoglycate; salts of nedocromil, e.g. nedocromil sodium; inhaled steroids such as beclomethasone dipropionate, tipredane, budesonide and fluticasone; anticholinergic agents such as ipratropium bromide; bronchodilators, e.g. salmeterol, salbutamol,
15 reproterol, terbutaline, isoprenaline and fenoterol, and salts thereof. If desired a mixture of active ingredients, for example, a mixture of sodium cromoglycate and a bronchodilator, such as salbutamol, reproterol, isoprenaline, terbutaline, fenoterol or a salt of any one thereof, may be used.

Other active ingredients that may be mentioned include antihistamines, e.g.
20 clemastine, pentamidine and salts thereof, acetyl- β -methylcholine bromide; peptide hormones, e.g. insulin and amylin; bradykinin antagonists; PLA₂ inhibitors; PAF antagonists; lipoxygenase inhibitors; leukotriene antagonists; CNS active drugs, e.g. NMDA antagonists, glutamate antagonists, CCK agonists and antagonists; macrolide compounds, e.g. FK 506, rapamycin, cyclosporin and structurally related compounds;
25 vitamins; vaccines, e.g. MMR vaccine and polio vaccine; and vectors for gene therapy, e.g. plasmids containing genes intended to correct genetic disorders such as cystic fibrosis.

The powdered medicament will generally be administered as a composition including one or more additional pharmaceutically acceptable additives, e.g. a solid
30 carrier of larger particle size. The solid pharmaceutically acceptable carrier will generally be a non-toxic material chemically inert to the inhalation medicament but may, if so desired, also comprise larger particles of the inhalation medicament. Examples of carriers which may be used in the composition include a dextran, mannitol and,

preferably, lactose. A particularly preferred carrier is crystalline lactose.

The powdered medicament may also be formulated as a so-called "pelletised" composition, i.e. as soft pellets of diameter greater than 30 μm , each pellet comprising a plurality of individual particles loosely held together such that upon inhalation the pellets disintegrate to the constituent particles. Pelletised compositions may be prepared according to the method described in GB 1520247.

The particular formulation of powdered medicament contained in the capsule will, of course, depend upon the nature of the active ingredient.

The amount of powdered medicament contained in the capsule will depend on the desired dosage and the potency of the active ingredient, but will generally be from about 10 μg to 50 mg, e.g. 20 mg.

According to a further aspect of the invention there is provided a method for administering powdered inhalation medicament contained initially in a capsule having at least one aperture formed therein, which comprises inserting the capsule in a device consisting of a swirl chamber adapted to receive the medicament capsule; a mouthpiece communicating with the swirl chamber and separated therefrom by a grid; at least one air inlet in tangential communication with the swirl chamber whereby air can be drawn through the device via the mouthpiece to cause a swirling air flow through the chamber; and a cover member provided on the base of the swirl chamber remote from the mouthpiece, said cover being moveable between a first position in which a capsule can be inserted into the swirl chamber and a second position in which the capsule is retained in the swirl chamber, and drawing air through the device, such that the capsule rotates in the swirl chamber thereby dispensing the medicament contained therein.

The device according to the invention has advantages over known inhalation devices in that the medicament capsules do not need to be individually pierced by hand; the risk of capsule fragments being inhaled by the patient is substantially reduced; it is safe since there is no sharp piercing mechanism which could cause accidental injury to the patient, it is suitable for the administration of a wide variety of inhalation medicaments which may be contained in capsules of varying sizes; it gives improved capsule emptying; it is of a more compact design; manufacture of the device is considerably simplified since no capsule opening mechanism is required; it is easy to clean; and, since the device contains no internal moving parts, it is less prone to malfunction and therefore may have an extended lifetime.

A preferred embodiment of the invention will now be described, by way of illustration only, with reference to the accompanying drawings, in which:

Figure 1 is a perspective view of a device according to the invention with the mouthpiece cover in place,

5 Figure 2 is a perspective view of a device according to Figure 1 with the mouthpiece cover removed,

Figure 3 is a side view of the device of Figure 2,

Figure 4 is a longitudinal section of the device of Figure 3 with cover open, and without the mouthpiece cover,

10 Figure 5 is the same longitudinal section of the device as in Figure 4 but with cover closed, and

Figure 6 is a section along the line X-X of Figure 5.






An inhalation device according to the invention comprises a generally cylindrical swirl chamber (1) adapted to receive a capsule (not shown) of powdered inhalation
15 medicament having an aperture formed at each end. A mouthpiece (2), having a removable mouthpiece cover (3), extends from swirl chamber (1) and is separated therefrom by a grid (4). Two tangential air inlets (5, 5a) open into swirl chamber (1). When the mouthpiece cover (3) is in place on the device air inlets (5, 5a) are covered by extensions of the mouthpiece cover (6, 6a). The base of swirl chamber (1) remote
20 from mouthpiece (2) is provided with a cover (7) having a continuous substantially planar inner surface, the cover (7) being attached to the base of the swirl chamber (1) via hinge (8), thus allowing access to the swirl chamber (1) for insertion and removal of a capsule. The end of the cover (7) remote from the hinge (8) is adapted to resiliently engage the base of the swirl chamber (1).

25 In use, cover (7) is opened and a capsule (not shown) of inhalation medicament having an aperture at each end is inserted into swirl chamber (1). Cover (7) is then closed and the mouthpiece cover (3) removed thus exposing air inlets (5, 5a). The patient inhales through mouthpiece (2), thereby drawing air through tangential air inlets (5, 5a) into swirl chamber (1). The air flowing into swirl chamber (1) causes the capsule
30 to rotate thereby dispensing the medicament contained therein which is entrained into air flow (A) and inhaled by the patient. Once the medicament has been inhaled the mouthpiece cover (3) is replaced and cover (7) is opened to allow removal of the empty capsule.

CLAIMS

1. A device for the administration of powdered inhalation medicament contained initially in a capsule having at least one aperture formed therein, said device comprising a swirl chamber (1) adapted to receive the medicament capsule; a mouthpiece (2) communicating with the swirl chamber (1) and separated therefrom by a grid (4); at least one air inlet (5) in tangential communication with the swirl chamber (1) whereby air can be drawn through the device via the mouthpiece (2) to cause a swirling air flow through the swirl chamber (1); and a cover member (7), having a continuous substantially planar inner surface, provided on the base of the swirl chamber (1) remote from the mouthpiece (2); said cover (7) being moveable between a first position in which the capsule can be inserted into the swirl chamber (1) and a second position in which the capsule is retained in the swirl chamber (1) and rotates upon air being drawn through the device, thereby dispensing the medicament contained therein.
2. A device according to Claim 1 wherein the cover member (7) is in hinged engagement with the base of the swirl chamber (1).
3. A device according to Claim 1 or 2 which has two air inlets (5, 5a) in tangential communication with the swirl chamber (1).
4. A device according to any one of the preceding claims which is provided with a mouthpiece cover (3).
5. A device according to Claim 4, wherein the mouthpiece cover (3) is adapted to cover the mouthpiece (2) and the air inlet(s) (5) communicating with the swirl chamber (1).
6. A device according to Claim 5, wherein the mouthpiece cover (3) is provided with a protruding element(s) (6) adapted to cover the air inlet(s) (5).

1/2



2/2




Fig. 4




Fig. 5

Fig. 6

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 94/00388

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 A61M15/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 5 A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP,A,0 385 156 (PHIDEA SRL) 5 September 1990 cited in the application see claims; figures	1-5
Y	EP,A,0 333 334 (HARRIS PHARM. LTD) 20 September 1989 cited in the application see claims; figures 1-6 see column 5, paragraph 2; figures 7-9	1-5
A	FR,A,2 264 563 (I.S.F. SPA) 17 October 1975 see page 4, line 7 - line 24; figures 1-12 see figures 13,14	1,4-6
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

25 May 1994

Date of mailing of the international search report

08.06.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Villeneuve, J-M

INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/GB 94/00388

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A,4 069 819 (VALENTINI ET AL.) 24 January 1978 see abstract; figures 5,6 -----	1

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 94/00388

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0385156	05-09-90	DE-D- 69005849	24-02-94
		DE-T- 69005849	19-05-94
		ES-T- 2048874	01-04-94
		US-A- 5152284	06-10-92

EP-A-0333334	20-09-89	AU-A- 3293189	06-09-89
		DE-D- 68911003	13-01-94
		ES-T- 2047110	16-02-94
		WO-A- 8907464	24-08-89
		JP-T- 3505679	12-12-91
		US-A- 5070870	10-12-91

FR-A-2264563	17-10-75	AT-B- 347016	11-12-78
		AU-A- 7435974	29-04-76
		BE-A- 821152	16-04-75
		CA-A- 1046882	23-01-79
		CH-A- 572750	27-02-76
		DE-A,B,C 2449179	25-09-75
		GB-A- 1485163	08-09-77
		JP-C- 1212693	12-06-84
		JP-A- 50125595	02-10-75
		JP-B- 53046400	13-12-78
		LU-A- 71109	17-04-75
		NL-A- 7413625	22-09-75
		NL-A- 8403186	01-02-85
		SE-B- 411517	14-01-80
		SE-A- 7412974	19-09-75
		US-A- 3991761	16-11-76

US-A-4069819	24-01-78	BE-A- 804645	11-03-74
		DE-A- 2340526	31-10-74
		FR-A,B 2225176	08-11-74
		GB-A- 1396258	04-06-75
		JP-A- 49130094	12-12-74
